The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship between those charateristics and pathogenesis and prognostic factors in the real-world population. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.
Study Type
OBSERVATIONAL
Enrollment
2,000
The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGOS
Overall survival (OS) refers to the time from receiving the first dose to death from any cause
Time frame: Baseline up to data cut-off (Up to approximately 20 years)
PFS
Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.
Time frame: Baseline up to data cut-off (Up to approximately 20 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.